Tecasin Afib

admin

USES: This medication is used to treat certain types of serious (possibly fatal) irregular heartbeat (such as atrial fibrillation / flutter). It is used to restore normal heart rhythm and maintain a regular, steady heartbeat. Dofetilide is known as an anti-arrhythmic drug. Tikosyn (dofetilide) is an antiarrhythmic drug used to help keep the heart beating normally in people with certain heart rhythm disorders of the atrium (the upper chambers of the heart). Tikosyn is used in people with atrial fibrillation or atrial flutter. What Are Side Effects of Tikosyn? Common side effects of Tikosyn include.

Authors:
Lip GY, Banerjee A, Boriani G, et al.
Citation:
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest 2018;Aug 21:[Epub ahead of print].
  • Atrial fibrillation (AFib) is a type of arrhythmia, or abnormal heart rhythm. According to the American Heart Association, it affects about 2.7 million Americans. People with AFib have an irregular.
  • What is atrial fibrillation? Atrial fibrillation (AF or AFib) is the most common irregular heart rhythm that starts in the atria. Instead of the SA node (sinus node) directing the electrical rhythm, many different.
  • Wenxin Keli Early research shows the extract of a mixture of five different Chinese herbs may help treat occasional, or paroxysmal, AFib. But some people in those studies had problems when they.

The following are key points to remember from the 2018 CHEST Guideline and Expert Panel Report on Antithrombotic Therapy for Atrial Fibrillation (AF):

Med
  1. The American College of Chest Physicians (ACCP) has updated their 2012 guidelines on the use of antithrombotic medications for patients with atrial fibrillation (AF).
  2. They recommend the use of the CHA2DS2-VASc score in AF patients to estimate the risk of ischemic stroke and systemic embolism.
  3. For patients with nonvalvular AF who are at low risk of stroke (CHA2DS2-VASc score of 0 in men and 1 in women), they suggest no antithrombotic therapy.
  4. For patients with nonvalvular AF who have one or more nonsex CHA2DS2-VASc risk factors, they suggest oral anticoagulation rather than no therapy, aspirin therapy, or dual antiplatelet therapy.
  5. When selecting an oral anticoagulant, they recommend using a direct oral anticoagulant (DOAC) rather than dose-adjusted vitamin K antagonist therapy for eligible patients.
  6. For patients with prior unprovoked bleeding, bleeding on warfarin therapy, or at high risk for bleeding, they suggest using apixaban, edoxaban, or dabigatran 110 mg (where available).
  7. When using dose-adjusted vitamin K antagonist therapy, they recommend aiming for high-quality anticoagulation control (defined as a time in the therapeutic range [TTR] of >70%) and a target international normalized ratio (INR) range of 2.0-3.0. If the quality of vitamin K antagonist therapy is poor (TTR <65%), they recommend interventions to improve control, including more frequent INR tests, reviewing medication adherence, reviewing potential drug-drug interactions, and further education and counseling.
  8. They recommend addressing any modifiable bleeding risk factors (e.g., uncontrolled hypertension, labile INRs, concomitant use of aspirin or nonsteroidal anti-inflammatory drugs, excess alcohol use) for any patient treated with antithrombotic therapy.
  9. Any patient at high risk for bleeding (HAS-BLED score of ≥3) should be reviewed and followed frequently.
  10. For patients with AF >48 hours in duration (or of unknown duration), they recommend therapeutic anticoagulation for at least 3 weeks or undergoing transesophageal echocardiogram (TEE) prior to cardioversion. These patients should remain on anticoagulation for at least 4 weeks after successful cardioversion to sinus rhythm, regardless of baseline stroke risk.
  11. For patients with a known left atrial appendage thrombus detected on TEE, they recommend postponing cardioversion and continuing anticoagulation for another 4-12 weeks to allow thrombus resolution or endothelialization. The need for a repeat TEE can be individualized.
  12. For patients with AF undergoing coronary stenting, the use of multiple antithrombotics should be based on the risk of bleeding and the clinical presentation necessitating coronary stenting.
  13. AF patients undergoing elective coronary stent procedures should be treated with triple therapy for 1-3 months followed by dual therapy (anticoagulation plus clopidogrel) until 12 months, followed by anticoagulation monotherapy for patients with low bleeding risk (HAS-BLED score of 0-2). For patients with high bleeding risk (HAS-BLED ≥3), they recommend triple therapy for 1 month followed by dual therapy for 6 months, followed by oral anticoagulation monotherapy.
  14. AF patients undergoing coronary stent procedures for an acute coronary syndrome should receive triple therapy for 6 months followed by dual therapy (anticoagulation plus clopidogrel) until 12 months, followed by anticoagulation monotherapy for patients with low bleeding risk (HAS-BLED score of 0-2). Patients with high bleeding risk (HAS-BLED ≥3) should receive triple therapy for 1-3 months, followed by dual therapy up to 12 months, followed by anticoagulation monotherapy.
  15. In AF patients who have survived intracranial hemorrhage and are at high risk of recurrence (e.g., probable cerebral amyloid angiopathy), they suggest left atrial appendage occlusion.

Clinical Topics:Acute Coronary Syndromes, Anticoagulation Management, Arrhythmias and Clinical EP, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Prevention, Anticoagulation Management and ACS, Anticoagulation Management and Atrial Fibrillation, Implantable Devices, EP Basic Science, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Interventions and ACS, Interventions and Imaging, Interventions and Vascular Medicine, Echocardiography/Ultrasound, Hypertension

Keywords:Acute Coronary Syndrome, Anticoagulants, Arrhythmias, Cardiac, Aspirin, Atrial Appendage, Atrial Fibrillation, Brain Ischemia, Cerebral Amyloid Angiopathy, Echocardiography, Transesophageal, Electric Countershock, Embolism, Fibrinolytic Agents, Hemorrhage, Hypertension, Intracranial Hemorrhages, Myocardial Ischemia, Platelet Aggregation Inhibitors, Risk Factors, Secondary Prevention, Stents, Stroke, Thrombosis, Vitamin K, Vascular Diseases, Warfarin


< Back to Listings

Atrial fibrillation (AF or afib) is the most common irregular heartbeat and is characterized by heart palpitations, dizziness, and shortness of breath. This progressive and debilitating disease can lead to stroke, heart failure, and Alzheimer's disease, and can double your risk of death. Afib takes a physical toll, an emotional toll, and a financial toll on those who are living with it—not just the patient, but the family, too.

If you wonder whether you are at risk for atrial fibrillation, or whether you might have it already, or if you want to know how to manage afib now that you have been diagnosed, then you have come to the right place. StopAfib.org is here to help increase your knowledge about afib, to help improve your quality of life if you are living with it, and to help you avoid an afib-related stroke.

How StopAfib.org Can Help You

Afib

So let's Get Started Learning About Atrial Fibrillation.

News from StopAfib.org

Here are the most recent atrial fibrillation news stories. Sign up for our Newsletter on this page to be notified of the latest news stories.

See the News and Events page for other news, events, and video interviews with top afib doctors.

Tecasin Afib

Managing Afib During a Pandemic: Answering Your Vaccine Questions

Do you have questions? How to protect yourself. ... more

Our Gift to You: Watch the 2020 Patient Conference Opening Session

Answers to the Most Common Afib Patient Questions: Our Gift To You ... more

Complimentary: Get Back to Care Webinar Series

Tekocine Medication

To give you vital information to avoid missing out on the care you need during the pandemic ... more

The StopAfib.org Atrial Fibrillation Patient Conference Goes Virtual Oct. 30–Nov. 1

Anyone anywhere in the world can hear directly from the foremost experts in afib ... more

Afib News from the European Society of Cardiology 2020 Congress

New Atrial Fibrillation Science Presented at the ESC Congress 2020: The Digital Experience ... more

Webinar Replay is Now Available: How to Know When It’s Safe to Have an Afib Catheter Ablation

Dr. Suneet Mittal shares how to know if it’s safe to have an atrial fibrillation procedure during and after the COVID-19 pandemic ... more

The Heartline Study is a virtual heart health wellness study for people 65+

Can this study reduce the risk of strokes from atrial fibrillation? ... more

Introducing The StopAfib.org Library Collection of No-Cost Videos for Atrial Fibrillation Patients

Access Invaluable Patient Conference, Webinar, and Master Class Videos ... more

Tekasin Afib Med Side Effects

Coronavirus Resources for Those with Afib

Tykeson

Credible information on the coronavirus (COVID-19) ... more

Tickerson Heart Medication

Raising Awareness About Atrial Fibrillation on National TV

Watch the afib awareness segment on the Dr. Phil Show on April 10, 2019 ... more